In a significant advancement for cardiac care in India, a healthcare company Abbott has unveiled the XIENCE Sierra Everolimus Eluting Coronary Stent System. The company in a press statement on Friday said, this next-generation coronary stent offering a new standard of precision and care, marks a milestone in interventional cardiology.
The company further said that it aims to provide cardiologists with cutting-edge technology to address complex coronary cases effectively. The stent's innovative design, advanced technology, and superior deliverability promise enhanced safety and efficacy in treating blocked coronary arteries.
Percutaneous coronary intervention (PCI), commonly known as coronary angioplasty, is a minimally invasive procedure crucial for restoring blood flow to the heart. Abbott's XIENCE Sierra stent represents a significant evolution in this field, having an expanded expansion range and high longitudinal strength, ensuring stability and minimising risks during the procedure.
Tushar Sharma, General Manager for Abbott’s vascular business in India and South Asia, emphasised the importance of XIENCE Sierra's launch, stating, "With the rise in coronary artery disease cases in India, it’s crucial to equip physicians with advanced technologies for optimal stent implantation. XIENCE Sierra's enhanced design and improved deliverability empower physicians to address challenging lesions with precision, ultimately leading to better patient outcomes."
Cardiovascular diseases remain a leading cause of mortality in India, making advancements in cardiac care imperative.
